McKinsey and Company's involvement in boosting OxyContin sales for Purdue Pharma

McKinsey and Company agreed to pay $650 million to settle federal probes into its role in boosting OxyContin sales for Purdue Pharma. The settlement includes a deferred prosecution agreement and a guilty plea from a former senior partner for obstruction of justice. The company also apologized for its actions and agreed to refrain from work involving controlled substances in the future.

Supreme Court Decision on Purdue Pharma Bankruptcy

The Supreme Court struck down a controversial Purdue Pharma bankruptcy plan affecting compensation to thousands of opioid victims and sending legal shockwaves through the U.S. bankruptcy system.